Teva Pharmaceutical Industries annual total assets
2008
2009
2010
2011
2012
2013
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Teva Pharmaceutical Industries Total Assets Growth & History (TEVA)
Teva Pharmaceutical Industries's total assets was $40.75B for fiscal 2025.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $40.75B | $1.42B | +3.62% |
| 2024 | 2024-12-31 | $39.33B | −$4.15B | −9.55% |
| 2023 | 2023-12-31 | $43.48B | −$532.0M | −1.21% |
| 2022 | 2022-12-31 | $44.01B | −$3.65B | −7.67% |
| 2021 | 2021-12-31 | $47.67B | −$2.97B | −5.87% |
| 2020 | 2020-12-31 | $50.64B | −$6.83B | −11.88% |
| 2019 | 2019-12-31 | $57.47B | −$3.21B | −5.29% |
| 2018 | 2018-12-31 | $60.68B | −$9.93B | −14.07% |
| 2017 | 2017-12-31 | $70.61B | −$22.44B | −24.12% |
| 2016 | 2016-12-31 | $93.06B | — | — |
| 2013 | 2013-12-31 | $47.51B | −$3.10B | −6.13% |
| 2012 | 2012-12-31 | $50.61B | $467.0M | +0.93% |
| 2011 | 2011-12-31 | $50.14B | $11.99B | +31.43% |
| 2010 | 2010-12-31 | $38.15B | $4.94B | +14.88% |
| 2009 | 2009-12-31 | $33.21B | $290.0M | +0.88% |
| 2008 | 2008-12-31 | $32.92B | — | — |
Teva Pharmaceutical Industries quarterly total assets
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
As of Dec 31, 2014
As of Mar 31, 2015
As of Jun 30, 2015
As of Sep 30, 2015
As of Dec 31, 2015
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $39.86B | −$274.0M | −0.68% |
| Q1 2026 | 2026-03-31 | $40.04B | $1.63B | +4.23% |
| Q4 2025 | 2025-12-31 | $40.75B | $1.42B | +3.62% |
| Q3 2025 | 2025-09-30 | $39.86B | −$1.90B | −4.55% |
| Q2 2025 | 2025-06-30 | $40.13B | −$1.21B | −2.92% |
| Q1 2025 | 2025-03-31 | $38.41B | −$4.36B | −10.19% |
| Q4 2024 | 2024-12-31 | $39.33B | −$4.15B | −9.55% |
| Q3 2024 | 2024-09-30 | $41.76B | −$337.0M | −0.80% |
| Q2 2024 | 2024-06-30 | $41.34B | −$1.76B | −4.09% |
| Q1 2024 | 2024-03-31 | $42.77B | −$688.0M | −1.58% |
| Q4 2023 | 2023-12-31 | $43.48B | −$532.0M | −1.21% |
| Q3 2023 | 2023-09-30 | $42.09B | −$2.16B | −4.87% |
| Q2 2023 | 2023-06-30 | $43.10B | −$2.83B | −6.17% |
| Q1 2023 | 2023-03-31 | $43.46B | −$3.60B | −7.65% |
| Q4 2022 | 2022-12-31 | $44.01B | −$3.65B | −7.67% |
| Q3 2022 | 2022-09-30 | $44.25B | −$3.60B | −7.52% |
| Q2 2022 | 2022-06-30 | $45.93B | −$3.26B | −6.63% |
| Q1 2022 | 2022-03-31 | $47.06B | −$1.95B | −3.97% |
| Q4 2021 | 2021-12-31 | $47.67B | −$2.97B | −5.87% |
| Q3 2021 | 2021-09-30 | $47.85B | −$1.89B | −3.79% |
| Q2 2021 | 2021-06-30 | $49.20B | −$5.80B | −10.54% |
| Q1 2021 | 2021-03-31 | $49.00B | −$6.33B | −11.43% |
| Q4 2020 | 2020-12-31 | $50.64B | −$6.83B | −11.88% |
| Q3 2020 | 2020-09-30 | $49.74B | −$7.51B | −13.12% |
| Q2 2020 | 2020-06-30 | $54.99B | −$4.43B | −7.46% |
| Q1 2020 | 2020-03-31 | $55.33B | −$4.52B | −7.56% |
| Q4 2019 | 2019-12-31 | $57.47B | −$3.21B | −5.29% |
| Q3 2019 | 2019-09-30 | $57.25B | −$7.82B | −12.01% |
| Q2 2019 | 2019-06-30 | $59.42B | −$7.61B | −11.35% |
| Q1 2019 | 2019-03-31 | $59.85B | −$9.33B | −13.48% |
| Q4 2018 | 2018-12-31 | $60.68B | −$9.93B | −14.07% |
| Q3 2018 | 2018-09-30 | $65.06B | −$21.02B | −24.42% |
| Q2 2018 | 2018-06-30 | $67.03B | −$19.32B | −22.38% |
| Q1 2018 | 2018-03-31 | $69.18B | −$22.09B | −24.21% |
| Q4 2017 | 2017-12-31 | $70.61B | −$22.44B | −24.12% |
| Q3 2017 | 2017-09-30 | $86.08B | −$12.66B | −12.83% |
| Q2 2017 | 2017-06-30 | $86.36B | $28.43B | +49.09% |
| Q1 2017 | 2017-03-31 | $91.28B | $36.15B | +65.58% |
| Q4 2016 | 2016-12-31 | $93.06B | $38.82B | +71.59% |
| Q3 2016 | 2016-09-30 | $98.75B | $50.12B | +103.08% |
| Q2 2016 | 2016-06-30 | $57.92B | $7.55B | +14.99% |
| Q1 2016 | 2016-03-31 | $55.13B | $8.18B | +17.41% |
| As of Dec 31, 2015 | 2015-12-31 | $54.23B | $7.81B | +16.83% |
| As of Sep 30, 2015 | 2015-09-30 | $48.63B | $2.02B | +4.33% |
| As of Jun 30, 2015 | 2015-06-30 | $50.37B | $3.64B | +7.78% |
| As of Mar 31, 2015 | 2015-03-31 | $46.95B | $59.0M | +0.13% |
| As of Dec 31, 2014 | 2014-12-31 | $46.42B | −$1.09B | −2.29% |
| Q3 2014 | 2014-09-30 | $46.61B | −$1.24B | −2.60% |
| Q2 2014 | 2014-06-30 | $46.73B | −$769.0M | −1.62% |
| Q1 2014 | 2014-03-31 | $46.89B | −$1.18B | −2.45% |
| Q4 2013 | 2013-12-31 | $47.51B | −$3.10B | −6.13% |
| Q3 2013 | 2013-09-30 | $47.85B | −$1.73B | −3.49% |
| Q2 2013 | 2013-06-30 | $47.50B | −$1.38B | −2.82% |
| Q1 2013 | 2013-03-31 | $48.07B | −$2.40B | −4.76% |
| Q4 2012 | 2012-12-31 | $50.61B | $467.0M | +0.93% |
| Q3 2012 | 2012-09-30 | $49.58B | $8.30B | +20.11% |
| Q2 2012 | 2012-06-30 | $48.88B | $8.72B | +21.72% |
| Q1 2012 | 2012-03-31 | $50.47B | $11.22B | +28.58% |
| Q4 2011 | 2011-12-31 | $50.14B | $11.99B | +31.43% |
| Q3 2011 | 2011-09-30 | $41.28B | $2.24B | +5.74% |
| Q2 2011 | 2011-06-30 | $40.16B | $4.97B | +14.13% |
| Q1 2011 | 2011-03-31 | $39.25B | $5.20B | +15.28% |
| Q4 2010 | 2010-12-31 | $38.15B | $4.94B | +14.88% |
| Q3 2010 | 2010-09-30 | $39.04B | $5.74B | +17.24% |
| Q2 2010 | 2010-06-30 | $35.19B | $2.93B | +9.10% |
| Q1 2010 | 2010-03-31 | $34.05B | $1.81B | +5.61% |
| Q4 2009 | 2009-12-31 | $33.21B | $290.0M | +0.88% |
| Q3 2009 | 2009-09-30 | $33.30B | — | — |
| Q2 2009 | 2009-06-30 | $32.25B | — | — |
| Q1 2009 | 2009-03-31 | $32.24B | — | — |
| Q4 2008 | 2008-12-31 | $32.92B | — | — |
Teva Pharmaceutical Industries total assets trends
Over the last five fiscal years, Teva Pharmaceutical Industries's total assets decreased from $50.64B to $40.75B, a change of −$9.89B. The latest reported quarter, Q2 2026, shows $39.86B.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teva Pharmaceutical Industries source filings ↗